tramadol HCl/acetaminophen
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Migraine
Conditions
Migraine, Head Pain, Headache
Trial Timeline
Apr 1, 2003 → Aug 1, 2003
NCT ID
NCT00297375About tramadol HCl/acetaminophen
tramadol HCl/acetaminophen is a approved stage product being developed by Johnson & Johnson for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT00297375. Target conditions include Migraine, Head Pain, Headache.
What happened to similar drugs?
20 of 20 similar drugs in Migraine were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00297375 | Approved | Completed |
Competing Products
20 competing products in Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DFN-11 | Dr. Reddy's Laboratories | Phase 2 | 32 |
| DFN-15 Active | Dr. Reddy's Laboratories | Phase 3 | 37 |
| DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed) | Dr. Reddy's Laboratories | Phase 1 | 26 |
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 37 |
| DFN-02 | Dr. Reddy's Laboratories | Phase 3 | 37 |
| DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B) | Dr. Reddy's Laboratories | Phase 2 | 32 |
| DFN-15 | Dr. Reddy's Laboratories | Phase 2 | 32 |
| ABP-450 | AEON Biopharma | Phase 2 | 17 |
| Lasmiditan + Placebo | Eli Lilly | Phase 3 | 40 |
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 27 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | 29 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | 25 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 35 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 17 |
| Galcanezumab + Erenumab | Eli Lilly | Approved | 43 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2 | 35 |
| Galcanezumab + Rimegepant + Placebo + Placebo | Eli Lilly | Approved | 43 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 35 |